Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, 266 Fangzheng Ave, Shuitu Technology Development Zone, Beibei, 400714 Chongqing, China; Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, 55 Daxuecheng South Road, Shapingba, 401331 Chongqing, China.
Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, 55 Daxuecheng South Road, Shapingba, 401331 Chongqing, China.
J Control Release. 2021 Jan 10;329:454-467. doi: 10.1016/j.jconrel.2020.11.045. Epub 2020 Nov 27.
Intracellular methicillin-resistant Staphylococcus aureus (MRSA) is extremely difficult to remove by common antibiotics, leading to infection recurrence and resistance. Herein we report a novel exosome-based antibiotic delivery platform for eradicating intracellular MRSA, where mannosylated exosome (MExos) is employed as the drug carrier and preferentially taken up by macrophages, delivering lysostaphin (MExoL) and vancomycin (MExoV) to intracellular pathogens. Combination of MExoL and MExoV eradicated intracellular quiescent MRSA. Moreover, MExos rapidly accumulated in mouse liver and spleen, the target organs of intracellular MRSA, after intravenous (IV) administration. Thus, the MExos antibiotic delivery platform is a promising strategy for combating intracellular infection.
细胞内耐甲氧西林金黄色葡萄球菌（MRSA）很难被普通抗生素清除，导致感染复发和耐药性。在此，我们报告了一种基于外泌体的新型抗生素递药平台，用于消除细胞内 MRSA，其中甘露糖化外泌体（MExos）被用作药物载体，并被巨噬细胞优先摄取，递送达托霉素（MExoL）和万古霉素（MExoV）到细胞内病原体。MExoL 和 MExoV 的联合作用根除了细胞内静止期的 MRSA。此外，MExos 在静脉注射（IV）给药后迅速在小鼠的肝脏和脾脏等细胞内 MRSA 的靶器官中积累。因此，MExos 抗生素递药平台是一种有前途的对抗细胞内感染的策略。
J Antimicrob Chemother. 2007-11
Int J Nanomedicine. 2018-11-29
Antimicrob Agents Chemother. 2004-5
Extracell Vesicles Circ Nucl Acids. 2022-2-22
Exploration (Beijing). 2024-3-12
Nanomedicine (Lond). 2024
Pharmaceutics. 2024-7-7
Burns Trauma. 2024-7-18
Zotero 插件